FDA Approves Nerve-Stimulating Headband To Treat Migraines

MIAMI (CBSMiami) — For those who suffer from frequent migraines, there could be a quick fix and it's all in a headband.

The Food and Drug Administration was convinced that this could be helpful to those who suffer from this common type of headache with throbbing pain, nausea and light and sound sensitivity after reviewing Belgian studies on the device.

"People who really suffer with migraine are frequently in the emergency room, because they don't have something that sort of consistently helps," said neurologist Dr. Andrea Synowiec. "And for those people, I anticipate this is something they're very excited about."

The FDA approved Cefaly, a battery-operated band that goes across the forehead with self-adhesive electrodes. The idea is to electrically stimulate for 20 minutes a day the trigeminal nerve, which senses pain in the face and parts of the head.

The approval is based on a clinical trial of 67 adults who had at least two attacks a month. After going without medication for three months, they got either the actual device or a placebo device.

Those who got the actual device needed less medication and had fewer days with migraine.

"It's a novel way of looking at treatment, something that is non-pharmacologic, which for some people, the pills just make them feel sick," said Dr. Synowiec.

Also, a patient satisfaction study of more than 2,000 people in Belgium and France showed that 53 percent were happy with it and would buy one for continued use. It costs $300 in Canada.

Since it was just approved, doctors in the U.S. haven't had any experience with it.

"As larger groups of people are exposed to the treatment, it will become more apparent what is a big game changer and what really doesn't have much of an impact," said Dr. Synowiec.

Some people noticed a tingling feeling at the electrode sites. Some complained it made them sleepy. Some got a headache afterward.

Those who are looking for more information on Cefaly should check with their doctors.

Read more
f

We and our partners use cookies to understand how you use our site, improve your experience and serve you personalized content and advertising. Read about how we use cookies in our cookie policy and how you can control them by clicking Manage Settings. By continuing to use this site, you accept these cookies.